Sangamo Therapeutics (SGMO) said Thursday it signed a license agreement with Eli Lilly (LLY) to use its STAC-BBB adeno-associated virus capsid for diseases of the central nervous system.
The deal grants Lilly worldwide rights to use the STAC-BBB capsid for one initial target, with the option to add up to four more.
Sangamo said it will get an $18 million upfront license fee and may receive up to $1.4 billion in additional licensed target fees and milestone payments for the five potential disease targets, in addition to royalties on potential sales.
The shares of Sangamo Therapeutics were rising past 26% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.